Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB4A known ✓ | P04350 | 4/20 | 0.39 |
| ▸ | TUBB known ✓ | P07437 | 4/20 | 0.39 |
| ▸ | TUBA3C known ✓ | P0DPH7 | 4/20 | 0.39 |
| ▸ | TUBA1B known ✓ | P68363 | 4/20 | 0.39 |
| ▸ | TUBA4A known ✓ | P68366 | 4/20 | 0.39 |
| ▸ | TUBB4B known ✓ | P68371 | 4/20 | 0.39 |
| ▸ | TUBB3 known ✓ | Q13509 | 4/20 | 0.39 |
| ▸ | TUBB2A known ✓ | Q13885 | 4/20 | 0.39 |
| ▸ | TUBB8 known ✓ | Q3ZCM7 | 4/20 | 0.39 |
| ▸ | TUBA3E known ✓ | Q6PEY2 | 4/20 | 0.39 |
| ▸ | TUBA1A known ✓ | Q71U36 | 4/20 | 0.39 |
| ▸ | TUBA1C known ✓ | Q9BQE3 | 4/20 | 0.39 |
| ▸ | TUBB6 known ✓ | Q9BUF5 | 4/20 | 0.39 |
| ▸ | TUBB2B known ✓ | Q9BVA1 | 4/20 | 0.39 |
| ▸ | TUBB1 known ✓ | Q9H4B7 | 4/20 | 0.39 |
| ▸ | PDGFRB | P09619 | 4/20 | 0.41 |
| ▸ | KIT | P10721 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13252806 | 0.89 | PDGFRB (0.41) | PDGFRBTUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL412499 | 0.88 | PDGFRB (0.41) | PDGFRBTUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL13041102 | 0.88 | PDGFRB (0.41) | PDGFRBTUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL410435 | 0.84 | PDGFRB (0.40) | PDGFRBTUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL412480 | 0.84 | KDM4E (0.43) | KDM4EALDH1A1HPGDL3MBTL1 | |
| SCHEMBL411301 | 0.84 | ALDH1A1 (0.44) | KDM4EALDH1A1HPGDL3MBTL1 | |
| SCHEMBL414191 | 0.82 | KDM4E (0.46) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL412244 | 0.81 | MEN1 (0.48) | PDGFRBTUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL412221 | 0.80 | TUBB4A (0.43) | PDGFRBTUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL412601 | 0.78 | KDM4E (0.38) | KDM4EALDH1A1HPGDL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9175022-B2 | Compounds for the treatment of proliferative disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2015-11-03 | — | — | US | disclosed |
| US-20130338112-A1 | COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | SYNTA PHARMACEUTICALS CORP (US) | 2013-12-19 | — | — | US | disclosed |
| US-8501790-B2 | Compounds for the treatment of proliferative disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2013-08-06 | — | — | US | disclosed |
| EP-1919881-B1 | 1, 2, 3 -TRIAZOLES INHIBITORS OF TUBULIN POLYMERIZATION FOR THE TREATMENT OF POLIFERATIVE DISORDERS | SYNTA PHARMACEUTICALS CORP (US) | 2013-04-10 | — | — | EP | disclosed |
| US-20120022118-A1 | COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | SYNTA PHARMACEUTICALS CORP. | 2012-01-26 | — | — | US | disclosed |
| US-20100279410-A1 | COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | SYNTA PHARMACEUTICALS CORP. | 2010-11-04 | — | — | US | disclosed |
| US-7781462-B2 | Compounds for the treatment of proliferative disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2010-08-24 | — | — | US | disclosed |
| US-20100093670-A1 | Compounds for the treatment of angiogenesis | SYNTA PHARMACEUTICALS CORP. | 2010-04-15 | — | — | US | disclosed |
| EP-2059250-A2 | COMPOUNDS FOR THE TREATMENT OF ANGIOGENESIS | Synta Pharmaceuticals Corporation (US) | 2009-05-20 | — | — | EP | disclosed |
| EP-1919881-A1 | 1, 2, 3 -TRIAZOLES INHIBITORS OF TUBULIN POLYMERIZATION FOR THE TREATMENT OF POLIFERATIVE DISORDERS | Synta Pharmaceuticals Corporation (US) | 2008-05-14 | — | — | EP | disclosed |
| WO-2008033449-A2 | COMPOUNDS FOR THE TREATMENT OF ANGIOGENESIS | SYNTA PHARMACEUTICALS CORP. (US) | 2008-03-20 | — | — | WO | disclosed |
| US-20070238699-A1 | Compounds for the treatment of proliferative disorders | SYNTA PHARMACEUTICALS CORP. | 2007-10-11 | — | — | US | disclosed |
| WO-2007014198-A1 | 1, 2, 3 -TRIAZOLES INHIBITORS OF TUBULIN POLYMERIZATION FOR THE TREATMENT OF POLIFERATIVE DISORDERS | SYNTA PHARMACEUTICALS CORP. (US) | 2007-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070238699-A1 | Compounds for the treatment of proliferative disorders | RB1, MKI67, MAPRE1 | TUBB4A 18/4885TUBB 8/4885TUBA3C 74/4885 |
| US-20120022118-A1 | COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | RB1, MKI67, MAPRE1 | TUBB4A 18/4885TUBB 8/4885TUBA3C 74/4885 |
| US-20100093670-A1 | Compounds for the treatment of angiogenesis | FLT4, FLT1, TEK | TUBB4A 56/4885TUBB 86/4885TUBA3C 236/4885 |
| US-20130338112-A1 | COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | RB1, MKI67, MAPRE1 | TUBB4A 18/4885TUBB 8/4885TUBA3C 74/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.